2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-158007
    (RS)-G12Di-1
    		Inhibitor
    (RS)-G12Di-1 is a selective, covalent inhibitor of K-Ras-G12D.
    (RS)-G12Di-1
  • HY-P2360
    G12
    		98.98%
    G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12).
    G12
  • HY-N6674
    Diazepinomicin
    		Inhibitor 98.04%
    Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models.
    Diazepinomicin
  • HY-176134
    RP03707
    		Degrader
    RP03707 is a PROTAC based KRASG12D degrader (Red: KRASG12D inhibitor (HY-134813), black: linker, Blue: E3 ligase ligand).
    RP03707
  • HY-112491
    KRas G12C inhibitor 1
    		Inhibitor
    KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    KRas G12C inhibitor 1
  • HY-153413
    Kras4B G12D-IN-1
    		Inhibitor 98.01%
    Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566).
    Kras4B G12D-IN-1
  • HY-125847
    Salvianolic acid F
    		Inhibitor 99.72%
    Salvianolic acid F is a KRAS inhibitor. Salvianolic acid F inhibits cancer cell growth, invasion, and migration and induces apoptosis via the EP300/PI3K/AKT pathway in vitro. Salvianolic acid F inhibits the growth of KRAS-dependent lung cancer cells via the PI3K/AKT signaling pathway in vivo. Salvianolic acid F can be used in the research of various cancers, including lung and ovarian cancer.
    Salvianolic acid F
  • HY-161066
    KRAS G13D-IN-1
    		Inhibitor
    KRAS G13D-IN-1 (compound 41) is a selective and covalently reversible inhibitor of KRASG13D (IC50: 0.41 nM). The selectivity for KRASG13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRASG13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades.
    KRAS G13D-IN-1
  • HY-134977
    Atrovastatin-PEG3-FITC
    		Inhibitor 98.17%
    Atrovastatin-PEG3-FITC (compound S31) is a KRAS-PDEδ interaction inhibitor. Atrovastatin-PEG3-FITC acts as a ligand in fluorescence anisotropy assay.
    Atrovastatin-PEG3-FITC
  • HY-158310
    SOS1/EGFR-IN-1
    		Inhibitor 99.54%
    SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50=42.13±1.55 nM) and EGFR(IC50=1.01±0.04 nM) by inhibiting their downstream effector molecules. SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50=0.45±0.03 μM).
    SOS1/EGFR-IN-1
  • HY-B0105S
    Ketoconazole-d8
    		Inhibitor 99.79%
    Ketoconazole-d8 is the deuterium labeled Ketoconazole. Ketoconazole (R-41400) is an imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.
    Ketoconazole-d<sub>8</sub>
  • HY-139402
    MRTX849 acid
    		Inhibitor 99.84%
    MRTX849 acid, a derivative of MRTX849, can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC50s between 0.25 and 0.76 μM).
    MRTX849 acid
  • HY-P4869
    Biotin-KRpep-2d acetate
    		Inhibitor 99.13%
    Biotin-KRpep-2d acetate is a biotin-labeled KRpep-2d (HY-P3277).
    Biotin-KRpep-2d acetate
  • HY-154313
    Spiclomazine
    		Inhibitor 99.95%
    Spiclomazine (Clospirazine) is a potent mutant KRAS(G12C) inhibitor that selectively inhibits mutant KRAS-driven pancreatic cancer. Spiclomazine can eliminate KRas-GTP levels in KRAS-driven pancreatic cancer and effectively inhibit RAS-mediated signaling. Spiclomazine significantly inhibits tumor progression in mouse renal capsule xenotransplantation models.
    Spiclomazine
  • HY-117935
    GGTI-286 hydrochloride
    		Inhibitor
    GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM.
    GGTI-286 hydrochloride
  • HY-116269
    AZA197
    		Inhibitor 98.28%
    AZA197 is a selective small molecule inhibitor of Cdc42.AZA197 suppresses colon cancer cell proliferation, cell migration, invasion and increases apoptosis by down-regulating the PAK1 and ERK signaling pathways in vitro. AZA197 reduces tumor growth and significantly increases mouse survival in SW620 tumor xenografts.
    AZA197
  • HY-159652
    KRAS inhibitor-31
    		Inhibitor 99.36%
    KRAS inhibitor-31 (compound 33) is a KRAS inhibitor, with KD (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively.
    KRAS inhibitor-31
  • HY-P10051
    Cyclorasin 9A5
    		Inhibitor
    Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the Ras-Raf protein interaction with an IC50 of 120 nM.
    Cyclorasin 9A5
  • HY-P10650
    FAM49B (190-198) mouse
    		Inhibitor 99.76%
    FAM49B (190-198) mouse is a peptide fragment of FAM49B. FAM49B is a mitochondria-localized protein that regulates mitochondrial fission. FAM49B regulates mitochondrial function and integrity and tumor progression. FAM49B is also a negative regulator in T cell activation, it acts by repressing GTPase Rac activity and modulating cytoskeleton reorganization.
    FAM49B (190-198) mouse
  • HY-50733A
    CX-5011
    		Activator
    CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death.
    CX-5011
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.